Erythromycin

Primarily bacteriostatic against a wide range of organisms. Erythomycin is used as an alternative to penicillins in patients allergic to the latter group and as an alternative to tetracyclines in chlamydial infections. It is also used in diphtheria, pertussis, legionnaire’s disease and other respiratory tract infections. Also used topically in acne vulgaris.

Indications & Dosage:

Oral – Acute bacterial pharyngitis, Tonsillitis, Sinusitis, Otitis, Whooping Cough, Diphteria , Urogenital Infections – Usual dose 1g daily b.i.d/q.i.d. upto 4g/day can be given in severe infections. Legionnaire’s disease: 500 mg-1g 6 hourly. Streptococcal prophylaxis: 250 mg 12 hourly. Children: 30-50mg/kg/day in 3-4 divided doses. May be doubled in severe infections. Elderly: Maximum daily dose 1.5g

Composition:

Each Tablet Contains

(a) Erythromycin B.P. 250mg.

(b) Erythromycin B.P. 400mg.

Composition (Syrup 30/60ml):

Each 5ml Syrup contains

Erythromycin B.P. 100mg.

Safety Alert:

CL: Hypersens to erythromycin. History of jaundice.
SP: Cholestatic hepatitis & reversible abnormalities in LFT may be associated with prolonged or repeated therapy. History of hepatic disorders. Pregnancy, lactation.
INT POT-HAZ: Reduces therapeutic effect of penicillins. May potentiate action of carbamazepine, cyclosporine, theophylline and warfarin. Terfenqdine toxicity increased. Others – theophylline reduces plasma concentration of erythromycin. Increases serum digoxin levels. Antibacterialactivity potentiated by acetazolamide and sodium bicarbonate.
ADR POT-LT: Hepatotoxicity-cholestatic jaundice, raised serum transaminases and eosinophilia. Rarely Stevens-Johnsons syndrome. Others – Rash, Nausea, vomiting, G.I. discomfort, ototoxicity with high doses and associated renal failure.
LAB INT: False elevation of plasma-glutamic oxaloacetic transaminase if a colorimetric assay is used.
INT FOOD: Absorption affected to variable extent for different esters.
Base: Rate but not extent of absorption reduced.
Estolate: Peak levels and bioavailabilty increased.
Ethylsuccinate: Peak levels and bioavailabilty reduced.
Stearate: Bioavailability increased immediately before food but reduced when taken after food.

Norfloxacin

Effective against a wide range of Gram-positive and Gram-negative organisms including Pseudomonas. Penicillinase-producing gonococcal strains. Haemophilus influenzae are susceptible. Active against Gram-positive organisms such as Staphylococci including methicillin-resistant strains, Streptococci and Enterococci. Not active against anaerobes.

Indications & Dosage:

Oral -
Acute UTI: 400 mg b.i.d. 7-10 days. Recurrent or Chronic UTI: 400mg b.i.d. for 4 weeks and then 400 mg daily for 12 weeks.
Acute Gonococcal Infection : 800 mg single dose.
Genital infections: 400-800mg b.i.d. 7 days.
Gastro Intestinal Infections: 200-400mg b.i.d. 5 days.
Chemoprophylaxis for urological procedures in neutropenic patients:400mg b.i.d. for 8 weeks.

Composition:

Each Capsule Contains

Norfloxacine B.P. 400mg

Safety Alert:

CL: Hypersens to any quinolone, children, lactation, convulsions.
SP: Moderate renal impairment. History of convulsions. Do not exceed recommended dose. Ensure adequate hydration, urinary output. Patients predisposed to seizures. Pregnancy.
INT POT-LT: None Reported. Others – Nausea, vomiting, heart burn, constipation/diarrhea, headache, dizziness, depression, insomnia and seizures. Rash, dry mouth, fever, arthralgia. Elevated liver enzymes, urea and cretanine. Eosinophilia, neutropenia, thrombocytopenia and anaemia.
INT FOOD: Absorption reduced, especially with milk or yogurt.

Tetracycline

Bacteriostatic action through inhibition of protein synthesis. Effective against a wide range of organisms including Rickettsiae, Mycoplasma pneumoniae, pathogens causing lymphogranuloma venerium and granuloma inguinale, Borrelia recurrentis;Gram-negative organisms including Haemophilus influenzae, H.ducreyi, Pasteurella pestils, P.tularensis, Bacteroides spp., Bartonella, Vibro cholera, Brucella, E.coli, Enterobacter, Klebsiella, Shigella: Gram-positives such as Strep.pyogenes,Strep.Faecalis, Diplococcus pneumoniae, Staph.aureus, other pathogens such as Neisseria gonorrhoeae, Treponema pallidum, T-pertenue(yaws), Listeria monocytogenes, clostridium, Bacillus anthracis, Chlamydia trachomatis.

Indications & Dosage:

Infections caused by susceptible organisms: 1-2g/day in four divided doses.

Composition:

Each Capsule Contains

(a) Tetracycline B.P. 250mg

(b) Tetracycline B.P. 500mg

Safety Alert:

CL: Hypersens,SLE, pregnancy,neonates, lactation, children under 12 years.
SP: Renal/hepatic impairment. Avoid exposure to sunlight.
INT POT-HAZ: Reduces activity of some penicillin. Affects stability of anticoagulant control. Blood levels reduced by anticonvulsants. Increases blood levels of carbamazepine and phenytoin. Increases toxic effects of lithium. May increase digoxin levels. Others – Absorption reduced dairy products, iron, antacids.
ADR POT-LT: Rare, anaphylaxis, acute hepatic dysfunction. Others – G.I. disturbances, superinfections, photosensitivity,.Retardation of bone growth and tooth discolouration(when given to pregnant women and to children), hypersensitivity, blood dyscrasias.
LAB INT: False positive in fluorescent Hingerty method for urinary catecholamines.

Home        R & D        Quality Control        Services        Disclaimer     Contact Us     

Copyright © AshfordLaboratory.com | Design : Ashford Laboratory